eHealthMe - FDA and Social Media, Personalized eHealthMe - a cloud computing service for drugs

FDA and Social Media, Personalized

Advanced tools
Browse eHealthMe       Feature support groups

From FDA reports: drug interactions between Rocephin, Phenergan Hcl for a Male patient aged 21

This is a personalized study for a 21 year old male patient. The study is created by eHealthMe based on reports of 292 people who take the same drugs and have drug interactionsfrom FDA.

On Aug, 22, 2014: 292 people who reported to have interactions when taking Rocephin, Phenergan Hcl are studied

Trend of Rocephin, Phenergan Hcl's drug interactions, side effects, and effectiveness reports (2466655)

Information of the patient in this study:

Age: 21

Gender: male

Conditions: Antiallergic Therapy

Drugs taking:
- Rocephin: used for < 1 month
- Phenergan Hcl

Drug interactions have: Anaphylactic Shock

eHealthMe real world results:

Comparison with this patient's adverse outcomes among males aged 21 (±5):

InteractionNumber of reports
Anaphylactic Shock (severe and rapid and sometimes fatal hypersensitivity reaction to a substance)5 (100.00%)

Most common interactions experienced by males aged 21 (±5) in the use of Rocephin, Phenergan Hcl:

InteractionNumber of reports
Anaphylactic Shock (severe and rapid and sometimes fatal hypersensitivity reaction to a substance)5
Renal Cortical Necrosis (damage of kidney corticle)2
Renal Failure Acute (rapid kidney dysfunction)2
Renal Failure Chronic (long lasting kidney dysfunction)2
Hypocomplementaemia2
Rash Pruritic (redness with itching)2
Application Site Pain2
Injection Site Pain2
Vasoconstriction (constriction of blood vessels, which increases blood pressure)2
Rhabdomyolysis (a condition in which damaged skeletal muscle tissue breaks down)2

Most common interactions experienced by males aged 21 (±5) in long term use of Rocephin, Phenergan Hcl:

None.

For people in general (regardless of gender or age):

Comparison with this patient's adverse outcomes:

InteractionNumber of reports
Anaphylactic Shock (severe and rapid and sometimes fatal hypersensitivity reaction to a substance)13 (4.45%)

Most common interactions experienced by people in the use of Rocephin, Phenergan Hcl:

InteractionNumber of reports
Anxiety267
Dyspnoea (difficult or laboured respiration)228
Nausea (feeling of having an urge to vomit)156
Pain136
Abdominal Pain130
Pneumonia123
Pain In Jaw118
Osteonecrosis Of Jaw (death of bone of jaw)110
Chest Pain108
Back Pain102

Most common interactions experienced by people in long term use of Rocephin, Phenergan Hcl:

None.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

You can also:

NOTE: The study is based on active ingredients. Other drugs that have the same active ingredients are also considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

   

About - Terms of service - Privacy policy - Press - Advertise - Apps - Testimonials - Contact us

 
© 2014 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.